Analysts Set Glaukos Corporation (NYSE:GKOS) PT at $119.08

Shares of Glaukos Corporation (NYSE:GKOS) have been assigned an average rating of “Moderate Buy” from the sixteen research firms that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $119.0769.

Several equities analysts recently commented on GKOS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a report on Wednesday, October 8th. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a research report on Thursday, July 31st. UBS Group reiterated a “buy” rating and issued a $140.00 price objective on shares of Glaukos in a report on Monday, November 10th. Zacks Research lowered Glaukos from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 15th. Finally, Citigroup increased their target price on Glaukos from $110.00 to $113.00 and gave the company a “buy” rating in a report on Thursday, October 30th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Xponance Inc. boosted its position in Glaukos by 5.8% during the 1st quarter. Xponance Inc. now owns 3,843 shares of the medical instruments supplier’s stock valued at $378,000 after buying an additional 210 shares during the period. Victory Capital Management Inc. raised its stake in shares of Glaukos by 88.7% during the first quarter. Victory Capital Management Inc. now owns 140,411 shares of the medical instruments supplier’s stock valued at $13,819,000 after acquiring an additional 66,009 shares during the last quarter. OneAscent Financial Services LLC purchased a new stake in shares of Glaukos during the first quarter worth about $408,000. Teachers Retirement System of The State of Kentucky grew its stake in shares of Glaukos by 1.4% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 28,879 shares of the medical instruments supplier’s stock worth $2,842,000 after purchasing an additional 409 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in Glaukos during the 1st quarter valued at about $478,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $96.55 on Friday. The stock’s 50-day moving average is $84.23 and its 200 day moving average is $91.29. The stock has a market cap of $5.55 billion, a price-to-earnings ratio of -62.70 and a beta of 0.81. Glaukos has a 1-year low of $73.16 and a 1-year high of $163.71. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.11. The business had revenue of $133.54 million during the quarter, compared to analyst estimates of $122.55 million. Glaukos had a negative return on equity of 7.53% and a negative net margin of 18.65%.Glaukos’s revenue for the quarter was up 38.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.28) earnings per share. Glaukos has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Glaukos will post -1.08 EPS for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.